Daly Kieran R, Huang Laurence, Morris Alison, Koch Judy, Crothers Kristina, Levin Linda, Eiser Shary, Satwah Supriya, Zucchi Patricia, Walzer Peter D
Research Service 151, Veterans Affairs Medical Center, 3200 Vine Street, Cincinnati, OH 45220, USA.
Emerg Infect Dis. 2006 Aug;12(8):1231-7. doi: 10.3201/eid1708.060230.
We conducted a prospective pilot study of the serologic responses to overlapping recombinant fragments of the Pneumocystis jirovecii major surface glycoprotein (Msg) in HIV-infected patients with pneumonia due to P. jirovecii and other causes. Similar baseline geometric mean antibody levels to the fragments measured by an ELISA were found in both groups. Serum antibodies to MsgC in P. jirovecii patients rose to a peak level 3-4 weeks (p<0.001) after recovery from pneumocystosis; baseline CD4+ count > or =50 cells/microL and first episode of pneumocystosis were the principal host factors associated with this rise (both p<0.001). Thus, MsgC shows promise as a serologic reagent and should be tested further in clinical and epidemiologic studies.
我们对因耶氏肺孢子菌及其他病因导致肺炎的HIV感染患者，开展了一项关于对耶氏肺孢子菌主要表面糖蛋白（Msg）重叠重组片段的血清学反应的前瞻性试点研究。两组患者通过酶联免疫吸附测定法测得的针对这些片段的基线几何平均抗体水平相似。耶氏肺孢子菌患者体内针对MsgC的血清抗体在肺孢子菌病康复后3至4周升至峰值水平（p<0.001）；基线CD4+计数≥50个细胞/微升以及首次发生肺孢子菌病是与该抗体升高相关的主要宿主因素（两者p<0.001）。因此，MsgC有望成为一种血清学试剂，应在临床和流行病学研究中进一步进行检测。
